ArticleCHEST critical care2025
Improvements in Vasopressor Requirements With Venovenous Extracorporeal Membrane Oxygenation.
Article in CHEST critical care, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Vasopressor Requirements after Initiation of Venovenous Extracorporeal Membrane Oxygenation in Patients with Severe Respiratory Failure.Annals of intensive care · 2026Article
- Response letter to "Venovenous extracorporeal membrane oxygenation initiation and reduction in vasopressor requirements".Annals of intensive care · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Background: Veno-venous extracorporeal membrane oxygenation (V-V ECMO) is increasingly used for severe respiratory failure. Some ECMO clinicians may view concurrent vasopressors as a contraindication for V-V ECMO. However, we noted improved vasopressor requirements after V-V ECMO cannulation. Research Question: How does V-V ECMO affect vasopressor requirements in patients with respiratory failure? Methods: Retrospective review of all V-V ECMO initiations from 12/2016-12/31/2023 at a large volume ECMO center. The change in norepinephrine equivalent dose and number of continuous intravenous vasopressors were determined immediately prior to, and 24 hours post V-V ECMO cannulation. This change was assessed by Wilcoxon signed-rank tests and their associations with potential predictor variables (pH, P Results: 205 patients received V-V ECMO during this time, with 108 on vasopressors at ECMO cannulation and included in this analysis. The mean norepinephrine equivalent dose at ECMO initiation (0.23±0.29 mcg/kg/min) to 24 hours post ECMO (0.14±0.23 mcg/kg/min) significantly (p<0.001) decreased. The number of pressors at ECMO initiation (1.69±0.92) to 24 hours later (1.29±1.04) significantly (p<0.001) decreased. There was a significant decrease in PEEP, mean airway pressure, and P Interpretation: Patients' vasopressor requirements significantly decreased 24 hours post V-V ECMO initiation, with a change in pH weakly associated with vasopressor improvement. Requirement of vasopressors, even norepinephrine equivalent dose of ≥0.3 mcg/kg/min at time of ECMO consideration, is not a clear contraindication to ECMO candidacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.